Multi-modal bioprobe for bladder cancer imaging and photodynamic therapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9840522
APP PUB NO 20170107238A1
SERIAL NO

15352561

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a new generation of PDT agents based on porphyrin-lanthanide complexes with specific functional groups which can specifically localize on particular tumors, and their PDT processes can be monitored via NIR emission from erbium. In particular, the present invention provides a multi-modal lanthanide-porphyrin PDT agent (Er—R3) that are capable of killing the bladder tumor cells selectivity via 1O2 from porphyrin moiety and affording the fluorescence imaging simultaneously upon Er—R3 binding with the integrin αvβ3 isoform in bladder cancer cells.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
HONG KONG BAPTIST UNIVERSITYKOWLOON TONG KOWLOON HONG KONG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Wong, Ka Leung Hong Kong, HK 12 28
Wong, Wai Kwok Hong Kong, HK 8 8

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 12, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 12, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00